> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/bre-001/bre-039.md).
# BRE 039
## TTFields, Doxorubicin, Radiation, and Combination Amplification in Lung Cancer
**Clinical Cancer Name:** Non-Small Cell Lung Cancer\
**Common Cancer Name:** Lung Cancer
## Source
Lee, W. S., & Kim, E. H. (2022).
*Combination therapy of Doxorubicin with TTFields and radiation: newer approaches to combat lung cancer.*
*American Journal of Cancer Research, 12(6), 2673–2685.*
***
## BRS Score
**BRS:** 8.8 / 10\
**STEMD:** S9 / T8 / E8 / M9 / D10\
**External Evidence Level:** Moderate experimental in-vitro combination evidence
## Score Interpretation
BRE-039 receives a strong BRS because it provides direct in-vitro evidence that TTFields reduced lung cancer viability, proliferation, colony formation, migration, and invasion. It also shows that doxorubicin enhanced TTFields efficacy and that the triple combination of TTFields, doxorubicin, and radiation produced the strongest response.
***
## Entry Summary
BRE-039 asks a lung cancer question:
Can TTFields make chemotherapy and radiation work better together against lung cancer cells?
This study tested non-small cell lung cancer cell lines A549 and H460 using TTFields, doxorubicin, and radiation.
In simple language:
Electric fields weakened lung cancer cells in the lab. When chemotherapy and radiation were added, the effect became stronger.
***
## What BREXAtlas Found
BREXAtlas identifies this primary chain:
TTFields\
↓\
ROS increase\
↓\
Caspase-3 activation\
↓\
Apoptosis\
↓\
Reduced viability
The combination chain is:
TTFields\
+\
Doxorubicin\
↓\
Enhanced oxidative stress\
↓\
Enhanced apoptosis\
↓\
Reduced proliferation
The triple-combination chain is:
TTFields\
+\
Doxorubicin\
+\
Radiation\
↓\
Replication stress\
↓\
DNA damage\
↓\
ROS escalation\
↓\
Apoptotic collapse\
↓\
Maximum tumor suppression
This makes BRE-039 important because it strengthens the idea that TTFields may amplify conventional cancer treatments by increasing stress beyond what cancer cells can survive.
***
## Questions This BRE Helps Answer
What lung cancer models were studied?
What BREXAtlas found:\
BRE-039 studied A549 and H460, both non-small cell lung cancer models.
What frequency was used?
What BREXAtlas found:\
The study used TTFields at 150 kHz and 0.9 V/cm.
Why does doxorubicin matter?
Doxorubicin is a chemotherapy drug that can damage cancer cells.
What BREXAtlas found:\
Doxorubicin enhanced TTFields efficacy in the lung cancer models tested.
Why does radiation matter?
Radiation can damage cancer-cell DNA.
What BREXAtlas found:\
The strongest response came from the triple combination: TTFields + doxorubicin + radiation.
***
## Study Classification
| Category | Classification |
| -------------------------------------- | ----------------------------------------------- |
| Study Type | Experimental in-vitro combination therapy study |
| Tissue Category | Lung cancer / NSCLC |
| Cell Lines | A549, H460 |
| Frequency | 150 kHz |
| Field Strength | 0.9 V/cm |
| Combination Agents | Doxorubicin and radiation |
| Direct TTFields Evidence | Yes |
| Direct Combination Evidence | Yes |
| Suitable for Lung Cancer Index | Yes |
| Suitable for Combination Therapy Index | Yes |
| Suitable for ROS / Apoptosis Index | Yes |
***
## Mechanisms
**MEC-003: DNA Repair Interference**
Radiation-related DNA damage may be amplified when TTFields and doxorubicin are combined.
**MEC-018: Replication Stress**
The triple combination is linked with replication stress and DNA damage.
**MEC-031: Mitochondrial Electrical Stress**
BRE-039 strengthens the existing mitochondrial-electrical ontology but does not independently create a new mitochondrial mechanism.
**MEC-032: ROS-Electromagnetic Coupling**
TTFields increased ROS production and helped drive apoptosis.
**MEC-050: TTFields Chemotherapy Co-Amplification**
TTFields amplified doxorubicin response in lung cancer models.
**MEC-093: Triple-Modality Stress Amplification**
BRE-039 supports a combined stress model where electric fields, chemotherapy, and radiation converge on cancer-cell collapse.
***
## Discoveries
**DISC-007: Replication Stress and DNA Vulnerability**
BRE-039 supports the idea that TTFields may contribute to DNA vulnerability when combined with radiation.
**DISC-020: Electromagnetic Mitochondrial Respiration Disruption**
BRE-039 strengthens ROS/electrical stress relationships but does not directly demonstrate mitochondrial respiration disruption.
**DISC-021: Clinical Systems-Level TTFields Integration**
BRE-039 supports the broader TTFields systems framework by showing compatibility with conventional treatment strategies.
**DISC-024: Triple-Combination Amplification in Lung Cancer**
BREXAtlas identifies this as a lung cancer combination discovery:
TTFields, doxorubicin, and radiation together produced the strongest suppression response in NSCLC models.
***
## Connections to Other BRE Entries
### Connected to BRE-018
BRE-018 showed TTFields could sensitize non-small cell lung cancer cells to radiation through DNA repair vulnerability.
BRE-039 expands the lung cancer combination pathway by adding doxorubicin and triple-modality stress.
### Connected to BRE-020
BRE-020 synthesized TTFields combination potential with radiation and chemotherapy.
BRE-039 provides direct lung cancer in-vitro support for that combination logic.
### Connected to BRE-033
BRE-033 showed TTFields plus sorafenib amplified ROS and apoptosis in liver cancer.
BRE-039 shows a similar stress-amplification logic in lung cancer using doxorubicin and radiation.
### Connected to BRE-035
BRE-035 showed direct mitochondrial respiration disruption under rotating magnetic fields.
BRE-039 strengthens ROS-electromagnetic coupling but does not directly measure mitochondrial respiration, SDH inhibition, or radical-pair mechanisms.
### Connected to BRE-038
BRE-038 focused on clinical tolerability of TTFields with temozolomide in glioblastoma.
BRE-039 is preclinical, but it supports the broader question of how TTFields can be safely and effectively combined with standard therapies.
***
## Research Gaps Identified
**RG-193: Triple-Combination Translation Gap**
More research is needed to determine whether TTFields + doxorubicin + radiation can translate beyond in-vitro lung cancer models.
**RG-194: Normal Lung Cell Safety Gap**
Future studies should compare effects on normal lung cells under the same conditions.
**RG-195: Sequencing Gap**
More work is needed to determine the best order and timing of TTFields, doxorubicin, and radiation.
**RG-196: ROS Threshold Gap**
More studies are needed to determine how much ROS increase is therapeutic versus harmful.
**RG-197: Clinical Tolerability Gap**
Clinical studies would need to evaluate whether triple therapy produces acceptable toxicity.
***
## Scientific Caution
BRE-039 supports in-vitro lung cancer combination effects, but it does not directly demonstrate electron transport chain disruption, succinate dehydrogenase inhibition, mitochondrial permeability transition, radical-pair mechanisms, or direct mitochondrial respiration changes.
***
## Why This Entry Matters
For researchers, BRE-039 provides a strong lung cancer combination model.
For patients and families, the simple idea is this:
Electric fields, chemotherapy, and radiation may work better together than alone in lung cancer cells studied in the lab.
This is not proof of a ready clinical treatment. It is evidence that combination strategies deserve further testing.
***
## Entry Conclusion
BRE-039 expands the clinical-applied TTFields section into lung cancer combination therapy.
BRE-018 established TTFields radiation sensitization in lung cancer.
BRE-039 adds doxorubicin and shows the strongest response when TTFields, doxorubicin, and radiation are combined.
The central question emerging from this entry is:
Can TTFields help chemotherapy and radiation work together more effectively against non-small cell lung cancer?
For BREXAtlas, BRE-039 is a key lung cancer entry because it connects electric fields, chemotherapy, radiation, ROS, apoptosis, and triple-modality treatment amplification.
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://www.brexatlas.org/bre-001/bre-039.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.